Abstract
A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts death. The effects of different antiretroviral therapy regimens on CD4/CD8 ratio recovery remains unclear. We performed a post hoc analysis of the MERIT study, a randomized, double-blind trial of maraviroc versus efavirenz in combination with zidovudine-lamivudine in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by a greater CD8+ T-cell decline.
Keywords:
CD4/CD8 ratio; HIV; T cells; T-cell activation; antiretroviral therapy; efavirenz; maraviroc.
Copyright © 2017 American Society for Microbiology.
Publication types
-
Clinical Trial, Phase II
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Alkynes
-
Anti-HIV Agents / therapeutic use*
-
Benzoxazines / therapeutic use*
-
Biomarkers / analysis
-
CD4-CD8 Ratio*
-
Cyclohexanes / therapeutic use*
-
Cyclopropanes
-
Double-Blind Method
-
Drug Administration Schedule
-
Drug Combinations
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / immunology
-
HIV Infections / mortality
-
HIV Infections / virology
-
HIV-1 / drug effects
-
HIV-1 / genetics
-
HIV-1 / immunology
-
Humans
-
Lamivudine / therapeutic use*
-
Male
-
Maraviroc
-
Middle Aged
-
RNA, Viral / antagonists & inhibitors
-
RNA, Viral / biosynthesis
-
RNA, Viral / genetics
-
Survival Analysis
-
Triazoles / therapeutic use*
-
Viral Load / drug effects
-
Zidovudine / therapeutic use*
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Biomarkers
-
Cyclohexanes
-
Cyclopropanes
-
Drug Combinations
-
RNA, Viral
-
Triazoles
-
lamivudine, zidovudine drug combination
-
Lamivudine
-
Zidovudine
-
efavirenz
-
Maraviroc